GeoVax Labs, Inc. (GOVX)
| Market Cap | 21.61M |
| Revenue (ttm) | 3.09M |
| Net Income (ttm) | -24.32M |
| Shares Out | 9.44M |
| EPS (ttm) | -7.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 629,108 |
| Open | 2.310 |
| Previous Close | 2.320 |
| Day's Range | 2.190 - 2.380 |
| 52-Week Range | 1.090 - 11.180 |
| Beta | 3.31 |
| Analysts | Strong Buy |
| Price Target | 14.20 (+520.09%) |
| Earnings Date | Nov 12, 2024 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price forecast is $14.2, which is an increase of 520.09% from the latest price.
News
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vacci...
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chai...
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancer...
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its...
GeoVax to Participate in Upcoming Investor Conferences in September
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announc...
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, ...
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale o...
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, ...
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet i...
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
Mpox outbreak: 5 stocks to watch out for as the emergency unfolds
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to sprea...
GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark R...
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company develop...
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor
GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Office...
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise...
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dis...
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: ...
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced ...